MedTrace Logo

Effect of Body Mass on Filgrastim Pharmacokinetics

NCT01719432 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2020-12-17

No results posted yet for this study

Summary

Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking Neupogen to determine if higher body weights affect drug exposure. The information gathered from this study will help understand if patients with higher body weights need a different dosing plan.

Patients in this study will have blood draws once before they take Neupogen and 6 times after they take the Neuopen (for a total of 24 hours). These patients will be in the hospital already and will not need to make additional trips back to have blood drawn. A total of about 5-6 tablespoons of blood will be drawn for this study. 15 obese patients and 15 matched, non-obese patients will be enrolled into this study.

Conditions

Sponsors & Collaborators

  • Aaron Cumpston, PharmD, BCOP

    lead OTHER

Principal Investigators

  • Aaron Cumpston, PharmD, BCOP · West Virginia University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-05
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01719432 on ClinicalTrials.gov